Skip to main content
. Author manuscript; available in PMC: 2017 Mar 22.
Published in final edited form as: Circulation. 2016 Feb 25;133(12):1181–1188. doi: 10.1161/CIRCULATIONAHA.115.020109

Figure 1.

Figure 1

Flow diagram of the MI-GENES Clinical Trial. Of the 2026 individuals from the Mayo Biobank who met the eligibility criteria, a random subset of 1000 was genotyped. Genotyping results passed quality control measures in 968 individuals. Recruitment was based on screening genotyping results in order to achieve the targeted enrollment goals of ~110 individuals with high GRS (≥1.1) and ~110 with average/low GRS (<1.1) with the expectation that approximately 10–20 study participants may withdraw from the study or be lost to follow-up. Participants who withdrew from the study stated that they could not fit the study visits into their schedule. (ASCVD: atherosclerotic cardiovascular disease; CHD: coronary heart disease; GRS: genetic risk score).